Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis

JACC: Cardiovascular Imaging

Volumn 9, Issue 11, 2016, Pages 1267-1277

  Raina, Sameer ^a   Lensing, Shelly Y ^a   Nairooz, Ramez S ^a   Pothineni, Naga Venkata K ^a   Hakeem, Abdul ^a,b   Bhatti, Sabha ^a   Pandey, Tarun ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b VA Central Arkansas Healthcare System   (United States)

Author keywords

cardiac amyloidosis; cardiac MRI; late gadolinium enhancement

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

AMYLOIDOSIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CONTRAST ENHANCEMENT; DATA BASE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; MORTALITY; MORTALITY RATE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHIES; CHI SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; FEMALE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR;

AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 84994474997     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2016.01.036     Document Type: Article

References (23)

1. 1 Kyle, R.A., Amyloidosis. Circulation 91 (1995), 1269–1271.
2. 2 Falk, R.H., Comenzo, R.L., Skinner, M., The systemic amyloidoses. N Engl J Med 337 (1997), 898–909.
3. 3 Dubrey, S.W., Cha, K., Simms, R.W., Skinner, M., Falk, R.H., Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 77 (1996), 313–315.
4. 4 Syed, I.S., Glockner, J.F., Feng, D., et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img 3 (2010), 155–164.
5. 5 Austin, B.A., Tang, W.H., Rodriguez, E.R., et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol Img 2 (2009), 1369–1377.
6. 6 Maceira, A.M., Prasad, S.K., Hawkins, P.N., Roughton, M., Pennell, D.J., Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson, 10, 2008, 54.
7. 7 Mekinian, A., Lions, C., Leleu, X., et al. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 123 (2010), 864–868.
8. 8 Migrino, R.Q., Christenson, R., Szabo, A., Bright, M., Truran, S., Hari, P., Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. BMC Med Phys, 9, 2009, 5.
9. 9 Ruberg, F.L., Appelbaum, E., Davidoff, R., et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103 (2009), 544–549.
10. 10 White, J.A., Kim, H.W., Shah, D., et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. J Am Coll Cardiol Img 7 (2014), 143–156.
11. 11 Fontana, M., Pica, S., Reant, P., et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132 (2015), 1570–1579.
12. 12 Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
13. 13 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
14. 14 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Contr Clin Trials 7 (1986), 177–188.
15. 15 Sterne, J.A., Egger, M., Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54 (2001), 1046–1055.
16. 16 Peters, J.L., Sutton, A.J., Jones, D.R., Abrams, K.R., Rushton, L., Comparison of two methods to detect publication bias in meta-analysis. JAMA 295 (2006), 676–680.
17. 17 Stijnen, T., Hamza, T.H., Özdemir, P., Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 29 (2010), 3046–3067.
18. 18 Kuruvilla, S., Adenaw, N., Katwal, A.B., Lipinski, M.J., Kramer, C.M., Salerno, M., Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in non ischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 7 (2014), 250–258.
19. 19 Green, J.J., Berger, J.S., Kramer, C.M., Salerno, M., Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img 5 (2012), 370–377.
20. 20 Pellikka, P.A., Holmes, D.R. Jr., Edwards, W.D., Nishimura, R.A., Tajik, A.J., Kyle, R.A., Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 148 (1988), 662–666.
21. 21 Selvanayagam, J.B., Leong, D.P., MR imaging and cardiac amyloidosis. Where to go from here?. J Am Coll Cardiol Img 3 (2010), 165–167.
22. 22 Saeed, M., Van, T.A., Krug, R., Hetts, S.W., Wilson, M.W., Cardiac MR imaging: current status and future direction. Cardiovasc Diagn Ther 5 (2015), 290–310.
23. 23 Dungu, J.N., Valencia, O., Pinney, J.H., et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. J Am Coll Cardiol Img 7 (2014), 133–142.